WATERTOWN, Mass., June 12, 2026 — GLOBE NEWSWIRE — Leads & Copy — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company developing novel oral small molecule degrader medicines for immunological diseases, announced today that results from the Phase 1 study of its investigational drug KT-621, a first-in-class, oral STAT6 degrader, in healthy Japanese adults were presented at the Japanese Dermatological Association (JDA) Annual Meeting. The presentation shared safety and pharmacokinetic/pharmacodynamic (PK/PD) data consistent with previously reported KT-621 clinical studies.
KT-621 is designed to target STAT6, the transcription factor central to Type 2 inflammation driven by IL-4/IL-13 signaling. The company is currently conducting parallel Phase 2b trials for KT-621 in atopic dermatitis and asthma. Data from the atopic dermatitis trial, BROADEN2, is anticipated by mid-2027, and data from the asthma trial, BREADTH, is expected by late 2027. These Phase 2b studies aim to accelerate KT-621 development for subsequent Phase 3 registration studies across multiple Type 2 inflammatory diseases.
In the Phase 1 trial involving 24 healthy Japanese adults, KT-621 demonstrated a favorable PK profile, including rapid absorption and dose-proportional increases in plasma exposure. The drug also showed rapid and sustained STAT6 degradation in blood, with median degradation of 98% or higher at Day 7 across both dose levels tested. The study, which was randomized, double-blind, and placebo-controlled, administered KT-621 or placebo once daily for seven days at two dose levels in a 3:1 ratio. KT-621 was well tolerated and exhibited a favorable safety profile at both doses.
These findings in healthy Japanese adults were comparable to data previously observed in non-Japanese adults and patients with moderate to severe atopic dermatitis, further supporting KT-621’s potential as an oral treatment for chronic Type 2 inflammatory diseases. The Phase 1 trial in Japan was designed to gather the necessary PK/PD and safety data required by regulators before initiating patient enrollment in Japan for the global Phase 2b studies.
Dr. Jared Gollob, Chief Medical Officer of Kymera Therapeutics, stated, “The consistency we’ve demonstrated across KT-621 Phase 1 studies, from robust STAT6 degradation to a favorable safety profile, reflects the strong fidelity of translation of this unique approach from preclinical to clinical settings and further highlights KT-621’s compelling profile.” He added, “We believe KT-621 has the potential to transform care through a truly novel oral treatment option for patients living with chronic Type 2 inflammatory conditions, and the data reported to date continue to support its advancement globally across multiple diseases, starting with atopic dermatitis and asthma.”
Previous Phase 1 data for KT-621 in non-Japanese healthy volunteers and patients with moderate to severe atopic dermatitis indicated rapid, deep, and sustained STAT6 degradation in blood and skin. These studies also showed robust reductions in disease-relevant Type 2 inflammatory biomarkers, meaningful improvements in clinical endpoints and patient-reported outcomes in atopic dermatitis, and positive results in patients with comorbid asthma and allergic rhinitis, all within a favorable safety profile.
KT-621 is an investigational, first-in-class, once-daily oral degrader of STAT6. It is being evaluated for its potential to treat over 140 million patients worldwide affected by Type 2 inflammatory diseases, including atopic dermatitis, asthma, COPD, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, prurigo nodularis, and bullous pemphigoid.
Kymera Therapeutics is a clinical-stage biotechnology company focused on developing medicines through targeted protein degradation (TPD). Founded in 2016, the company aims to address critical health problems with therapies that can potentially improve patients’ lives. Kymera is building a pipeline of oral small molecule degraders designed to offer convenient and effective treatments for immunological diseases and other conditions. The company has been recognized as one of Boston’s top workplaces for several years.
Source: Kymera Therapeutics, Inc.
